Brief: Ascletis Pharma Inc Updates On ASC47
18/12/2024 15:26
Dec 18 (Reuters) - Ascletis Pharma Inc 1672.HK :
* ASC47 IN COMBINATION WITH SEMAGLUTIDE DEMONSTRATED
SUPERIOR
WEIGHT LOSS TO SEMAGLUTIDE MONOTHERAPY IN A PRECLINICAL MODEL
Further company coverage: 1672.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ascletis Pharma
See all newsFactbox: Race to launch weight-loss pill heats up as Novo wins UK approval
Brief: Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development
Factbox: Race to launch weight-loss pill heats up as Lilly wins US approval
Brief: Ascletis Pharma FY Loss Attributable Rmb359.9 Million
Brief: Ascletis Pharma Expects To Submit IND Application To U.S. FDA For ASC39 In Q3 2026